113 related articles for article (PubMed ID: 22280162)
41. The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy.
Hao J; Xu H; Luo M; Yu W; Chen M; Liao Y; Zhang C; Zhao X; Jiang W; Hou S; Feng X; Zou K; Chen Y; Huang W; Guo W; Kang L; Deng W
J Invest Dermatol; 2018 Jan; 138(1):159-170. PubMed ID: 28899685
[TBL] [Abstract][Full Text] [Related]
42. Kenalog modified by ionizing radiation induces intrinsic apoptosis mediated by elevated levels of reactive oxygen species in melanoma cancer.
Kawala RA; Ramadhani FJ; Choi HJ; Lee EH; Park CH; Chung BY; Bai HW
Oncol Rep; 2019 Mar; 41(3):1837-1850. PubMed ID: 30569155
[TBL] [Abstract][Full Text] [Related]
43. Melanoma never says die.
Haass NK; Schumacher U
Exp Dermatol; 2014 Jul; 23(7):471-2. PubMed ID: 24684560
[TBL] [Abstract][Full Text] [Related]
44. Design and synthesis of pyrrolobenzodiazepine-gallic hybrid agents as p53-dependent and -independent apoptogenic signaling in melanoma cells.
Chou YW; Senadi GC; Chen CY; Kuo KK; Lin YT; Wang JJ; Lee JH; Wang YC; Hu WP
Eur J Med Chem; 2016 Feb; 109():59-74. PubMed ID: 26756315
[TBL] [Abstract][Full Text] [Related]
45. Apoptosis induction by 4-nerolidylcatechol in melanoma cell lines.
Brohem CA; Sawada TC; Massaro RR; Almeida RL; Rivelli DP; Ropke CD; da Silva VV; de Lima TM; Curi R; Barros SB; Maria-Engler SS
Toxicol In Vitro; 2009 Feb; 23(1):111-9. PubMed ID: 19059332
[TBL] [Abstract][Full Text] [Related]
46. Proteasome inhibition and ROS generation by 4-nerolidylcatechol induces melanoma cell death.
Brohem CA; Massaro RR; Tiago M; Marinho CE; Jasiulionis MG; de Almeida RL; Rivelli DP; Albuquerque RC; de Oliveira TF; de Melo Loureiro AP; Okada S; Soengas MS; de Moraes Barros SB; Maria-Engler SS
Pigment Cell Melanoma Res; 2012 May; 25(3):354-69. PubMed ID: 22372875
[TBL] [Abstract][Full Text] [Related]
47. New anti-cancer molecules targeting HSPA5/BIP to induce endoplasmic reticulum stress, autophagy and apoptosis.
Cerezo M; Rocchi S
Autophagy; 2017 Jan; 13(1):216-217. PubMed ID: 27791469
[TBL] [Abstract][Full Text] [Related]
48. Molecular targets in melanoma from angiogenesis to apoptosis.
Sosman JA; Puzanov I
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2376s-2383s. PubMed ID: 16609062
[TBL] [Abstract][Full Text] [Related]
49. Survivin suppression through STAT3/β-catenin is essential for resveratrol-induced melanoma apoptosis.
Habibie ; Yokoyama S; Abdelhamed S; Awale S; Sakurai H; Hayakawa Y; Saiki I
Int J Oncol; 2014 Aug; 45(2):895-901. PubMed ID: 24946930
[TBL] [Abstract][Full Text] [Related]
50. Oxalomalate reduces tumor progression in melanoma via ROS-dependent proapoptotic and antiangiogenic effects.
Kim SH; Kil IS; Kwon OS; Kang BS; Lee DS; Lee HS; Lee JH; Park JW
Biochimie; 2019 Mar; 158():165-171. PubMed ID: 30639360
[TBL] [Abstract][Full Text] [Related]
51. Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression.
Chaube B; Malvi P; Singh SV; Mohammad N; Meena AS; Bhat MK
Oncotarget; 2015 Nov; 6(35):37281-99. PubMed ID: 26484566
[TBL] [Abstract][Full Text] [Related]
52. Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents.
Berger Y; Bernasconi CC; Juillerat-Jeanneret L
Exp Biol Med (Maywood); 2006 Jun; 231(6):1111-9. PubMed ID: 16741059
[TBL] [Abstract][Full Text] [Related]
53. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
54. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
55. The in-vitro and in-vivo inhibitory activity of biflorin in melanoma.
Vasconcellos MC; Bezerra DP; Fonseca AM; Araújo AJ; Pessoa C; Lemos TL; Costa-Lotufo LV; de Moraes MO; Montenegro RC
Melanoma Res; 2011 Apr; 21(2):106-14. PubMed ID: 21346641
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and identification of small molecules that potently induce apoptosis in melanoma cells through G1 cell cycle arrest.
Dothager RS; Putt KS; Allen BJ; Leslie BJ; Nesterenko V; Hergenrother PJ
J Am Chem Soc; 2005 Jun; 127(24):8686-96. PubMed ID: 15954774
[TBL] [Abstract][Full Text] [Related]
57. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.
Wang YF; Jiang CC; Kiejda KA; Gillespie S; Zhang XD; Hersey P
Clin Cancer Res; 2007 Aug; 13(16):4934-42. PubMed ID: 17652623
[TBL] [Abstract][Full Text] [Related]
58. Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model.
Mathieu V; Le Mercier M; De Neve N; Sauvage S; Gras T; Roland I; Lefranc F; Kiss R
J Invest Dermatol; 2007 Oct; 127(10):2399-410. PubMed ID: 17495956
[TBL] [Abstract][Full Text] [Related]
59. NFATc2 is a potential therapeutic target in human melanoma.
Perotti V; Baldassari P; Bersani I; Molla A; Vegetti C; Tassi E; Dal Col J; Dolcetti R; Anichini A; Mortarini R
J Invest Dermatol; 2012 Nov; 132(11):2652-60. PubMed ID: 22718120
[TBL] [Abstract][Full Text] [Related]
60. [Examination of different factors influencing the vascularization of human cutaneous melanoma].
Kiss J
Magy Onkol; 2008 Dec; 52(4):385-9. PubMed ID: 19068467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
